A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Status:
Recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2
study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and
preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination
with cemiplimab in subjects with advanced solid tumors.